Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder.
Bladder cancer
Comparative effectiveness
Squamous cell carcinoma
Journal
European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
19
09
2018
revised:
12
10
2018
accepted:
07
11
2018
pubmed:
15
8
2019
medline:
1
6
2021
entrez:
15
8
2019
Statut:
ppublish
Résumé
While there is established evidence supporting the use of radical cystectomy (RC) and perioperative chemotherapy for muscle-invasive urothelial carcinoma of the bladder, such evidence does not exist for squamous cell carcinoma. We present the largest study to date of patients with squamous cell carcinoma and compare the effectiveness of possible treatment regimens for overall survival. The National Cancer Data Base was queried for cases of localized, muscle-invasive pure squamous cell bladder cancer, classified as clinical stage T2/3N0M0. Permutations of surgery (RC), chemotherapy, and external beam radiation were selected. A multinomial propensity score method was used to create treatment weights based on clinical characteristics predicting the probability of treatment receipt. These were then applied in weighted Cox proportional hazards models to assess the comparative effectiveness of treatments for overall survival, adjusting for age, TNM clinical stage, Charlson comorbidity index, race, sex, and facility and county level variables. A total of 828 cases were included, comprising 465 RC alone, 53 neoadjuvant chemotherapy+RC, 48 RC+adjuvant chemotherapy, 72 chemotherapy alone, 88 radiation alone, and 102 chemoradiation cases. On weighted regression, RC treatment with or without perioperative chemotherapy was associated with significantly better overall survival compared to the other treatment modalities; chemotherapy alone, radiation alone, and chemoradiation were associated with a hazard ratio (HR) of death of 2.43 (95% confidence interval [CI] 1.65-3.59), 4.78 (95% CI 3.33-6.86), and 1.61 (95% CI 1.16-2.25), respectively, compared to RC alone (all p<0.005). A combination of RC and neoadjuvant chemotherapy was comparable to RC alone, with HR of death 1.33 (95% CI 0.89-1.98). The combination of RC and adjuvant chemotherapy was also similar to RC alone (HR 1.11, 95% CI 0.66-1.85). These findings are limited by small numbers and the retrospective nature of the study. RC with or without perioperative chemotherapy should be considered an upfront therapy for squamous cell carcinoma of the bladder. Using a national database, we compared treatments for muscle-invasive squamous cell bladder cancer. Patients undergoing radical cystectomy with or without chemotherapy had longer survival. Radical cystectomy with or without chemotherapy should be the standard of care for this disease.
Sections du résumé
BACKGROUND
While there is established evidence supporting the use of radical cystectomy (RC) and perioperative chemotherapy for muscle-invasive urothelial carcinoma of the bladder, such evidence does not exist for squamous cell carcinoma.
OBJECTIVE
We present the largest study to date of patients with squamous cell carcinoma and compare the effectiveness of possible treatment regimens for overall survival.
DESIGN, SETTING, AND PARTICIPANTS
The National Cancer Data Base was queried for cases of localized, muscle-invasive pure squamous cell bladder cancer, classified as clinical stage T2/3N0M0. Permutations of surgery (RC), chemotherapy, and external beam radiation were selected.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
A multinomial propensity score method was used to create treatment weights based on clinical characteristics predicting the probability of treatment receipt. These were then applied in weighted Cox proportional hazards models to assess the comparative effectiveness of treatments for overall survival, adjusting for age, TNM clinical stage, Charlson comorbidity index, race, sex, and facility and county level variables.
RESULTS AND LIMITATIONS
A total of 828 cases were included, comprising 465 RC alone, 53 neoadjuvant chemotherapy+RC, 48 RC+adjuvant chemotherapy, 72 chemotherapy alone, 88 radiation alone, and 102 chemoradiation cases. On weighted regression, RC treatment with or without perioperative chemotherapy was associated with significantly better overall survival compared to the other treatment modalities; chemotherapy alone, radiation alone, and chemoradiation were associated with a hazard ratio (HR) of death of 2.43 (95% confidence interval [CI] 1.65-3.59), 4.78 (95% CI 3.33-6.86), and 1.61 (95% CI 1.16-2.25), respectively, compared to RC alone (all p<0.005). A combination of RC and neoadjuvant chemotherapy was comparable to RC alone, with HR of death 1.33 (95% CI 0.89-1.98). The combination of RC and adjuvant chemotherapy was also similar to RC alone (HR 1.11, 95% CI 0.66-1.85). These findings are limited by small numbers and the retrospective nature of the study.
CONCLUSIONS
RC with or without perioperative chemotherapy should be considered an upfront therapy for squamous cell carcinoma of the bladder.
PATIENT SUMMARY
Using a national database, we compared treatments for muscle-invasive squamous cell bladder cancer. Patients undergoing radical cystectomy with or without chemotherapy had longer survival. Radical cystectomy with or without chemotherapy should be the standard of care for this disease.
Identifiants
pubmed: 31411987
pii: S2588-9311(18)30195-0
doi: 10.1016/j.euo.2018.11.003
pii:
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-514Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.